In a trial of 61 people with advanced pancreatic cancer, tumours stopped growing in 90 percent of them and vanished from scans entirely in one in 12.
Those numbers, presented Thursday at the EORTC–NCI–AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, represent the largest single jump in pancreatic cancer outcomes in decades.
The disease kills roughly 10,000 people a year in the UK and more than 10,000 in the United States, where it accounts for about 3 percent of all cancers but 8 percent of cancer deaths. Half of patients die within three months of diagnosis; only 3 percent survive five years once the cancer has spread.
“This is the closest to cure,” said Dr Wungki Park, a gastrointestinal medical oncologist at Memorial Sloan Kettering Cancer Center in New York who presented the findings. “We are beginning to see not only a higher percentage of tumour response rates, but also deeper responses and a near doubling in the duration of disease control, which may eventually translate into longer survival.”
The drug, daraxonrasib, is a KRAS inhibitor — a pill that locks onto the mutated protein driving most pancreatic tumours and switches it off. KRAS has long been nicknamed the “Death Star” because it was considered undruggable; more than nine in ten pancreatic cancers carry a KRAS mutation.
Earlier data on daraxonrasib alone, in about 500 previously treated patients, showed median survival of 13.2 months versus 6.7 months on chemotherapy. The new trial tested the pill combined with standard chemotherapy in newly diagnosed patients.

The numbers that shifted the goalposts
After a median follow-up of 18 months, 76.6 percent of patients on the combination were still alive. Historical one-year survival on chemotherapy alone sits at 40–45 percent. Just over 60 percent saw their tumours shrink or disappear; in 8 percent — one in 12 — CT scans showed no detectable cancer. Some patients have not relapsed during the entire follow-up period.
Dr Park put it plainly: “The median follow-up is 18 months. Just imagine, in an average of 18 months your disease just disappears on the CT scan… that’s closest to complete remission… it’s incredible.”
What “undruggable” meant — and why this cracks it open
KRAS sits on the inner surface of the cell membrane, smooth and featureless, offering no obvious pocket for a drug to grab. For forty years it defeated every attempt. Daraxonrasib binds a specific pocket on the KRAS G12D variant, the most common mutation in pancreatic cancer, and traps the protein in its inactive state.
Dr Sam Godfrey of Cancer Research UK: “What this new drug has done is it’s found a way of drugging the undruggable. We are finally seeing progress in pancreatic cancer which is so long overdue.”

Michelle Mitchell, chief executive of Cancer Research UK, called it “the biggest leap forward we’ve seen in decades for pancreatic cancer patients and could offer real hope to people facing one of the deadliest and most difficult-to-treat cancers.”
The cautions the specialists insist on
No one is using the word cure. The median follow-up is 18 months — too short to know whether the disappearances are durable. Cancer can return even when scans are clear. Prof Elena Garralda, chair of the EORTC symposium, said the results are exciting because they show the combination could potentially significantly improve patients’ overall survival, as well as the time before tumours start to grow again, but longer trials are essential.

“Cancer can come back and even if scans show there is no sign of it, you don’t necessarily know you are cancer-free until more time has passed,” Dr Godfrey told the BBC.
Daraxonrasib is already approved in the United States for previously treated KRAS G12D-mutated pancreatic cancer. The combination with frontline chemotherapy has not yet been assessed for NHS use in the UK. Similar KRAS mutations appear in lung, ovarian and other cancers, raising the possibility that the same strategy could spread beyond pancreatic disease — but that, too, awaits data.
Dr Rachna Shroff, a gastrointestinal cancer specialist at the University of Arizona, told The Telegraph she “started crying in the clinic” when she read the earlier survival data. The latest results deepen that signal. The question now is whether the extra months become years, and whether the one in twelve becomes one in six, one in four — or whether the disease finds its usual way back.